Information to Consider for Cigarettes

The information included in this appendix reflects deficiencies frequently seen in previous SE Reports for cigarettes that FDA has reviewed. It should be noted that, although this information is specific to cigarettes, some of it may not be applicable to your SE Report. To the extent that it is applicable, you can use this information to determine whether your SE Report should be amended prior to FDA’s review of your SE Report.

**Identification of the New and Predicate Tobacco Products**

Unique identification is an important element for new and predicate tobacco products. Unique identification is necessary so that FDA can accurately identify which products should be compared for a determination of substantial equivalence. Without unique identification, it is difficult for FDA to begin a scientific comparison to determine substantial equivalence.

Unique identification may include, but is not limited to, attributes such as brand, name, descriptors, packaging, size, count, and unit of use. You should provide the following information to uniquely identify the new and predicate tobacco products:

- The manufacturer
- Product name, including the brand and subbrand
- Product category, product subcategory, and product properties, as provided in Table 1
Table 1. Cigarette Subcategory and Corresponding Product Properties

<table>
<thead>
<tr>
<th>Cigarette Subcategory</th>
<th>Product Properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combusted, Filtered</td>
<td>• Package type (e.g., hard pack, soft pack, clam shell)</td>
</tr>
<tr>
<td></td>
<td>• Package quantity (e.g., 20 cigarettes, 25 cigarettes)</td>
</tr>
<tr>
<td></td>
<td>• Length (e.g., 89 millimeter (mm), 100 mm)</td>
</tr>
<tr>
<td></td>
<td>• Diameter (e.g., 6 mm, 8.1 mm)</td>
</tr>
<tr>
<td></td>
<td>• Ventilation (e.g., none, 10%, 25%)</td>
</tr>
<tr>
<td></td>
<td>• Characterizing Flavor(s)(^1) (e.g., none, tobacco, menthol)</td>
</tr>
<tr>
<td></td>
<td>• Additional properties needed to uniquely identify the tobacco product (if applicable)</td>
</tr>
<tr>
<td>Combusted, Non-filtered</td>
<td>• Package type (e.g., hard pack, soft pack, clam shell)</td>
</tr>
<tr>
<td></td>
<td>• Package quantity (e.g., 20 cigarettes, 25 cigarettes)</td>
</tr>
<tr>
<td></td>
<td>• Length (e.g., 89 mm, 100 mm)</td>
</tr>
<tr>
<td></td>
<td>• Diameter (e.g., 6 mm, 8.1 mm)</td>
</tr>
<tr>
<td></td>
<td>• Characterizing Flavor(s) (e.g., none, tobacco, menthol)</td>
</tr>
<tr>
<td></td>
<td>• Additional properties needed to uniquely identify the tobacco product (if applicable)</td>
</tr>
<tr>
<td>Combusted, Other</td>
<td>• Package type (e.g., hard pack, soft pack, clam shell)</td>
</tr>
<tr>
<td></td>
<td>• Package quantity (e.g., 20 cigarettes, 25 cigarettes)</td>
</tr>
<tr>
<td></td>
<td>• Length (e.g., 89 mm, 100 mm)</td>
</tr>
<tr>
<td></td>
<td>• Diameter (e.g., 6 mm, 8.1 mm)</td>
</tr>
<tr>
<td></td>
<td>• Ventilation (e.g., none, 10%, 25%)</td>
</tr>
<tr>
<td></td>
<td>• Characterizing Flavor(s) (e.g., none, tobacco, menthol)</td>
</tr>
<tr>
<td></td>
<td>• Additional properties needed to uniquely identify the tobacco product (if applicable)</td>
</tr>
<tr>
<td>Non-Combusted(^2)</td>
<td>• Package type (e.g., hard pack, soft pack, clam shell)</td>
</tr>
<tr>
<td></td>
<td>• Package quantity (e.g., 20 cigarettes, 25 cigarettes)</td>
</tr>
<tr>
<td></td>
<td>• Length (e.g., 89 mm, 100 mm)</td>
</tr>
<tr>
<td></td>
<td>• Diameter (e.g., 6 mm, 8.1 mm)</td>
</tr>
<tr>
<td></td>
<td>• Ventilation (e.g., none, 10%, 25%)</td>
</tr>
<tr>
<td></td>
<td>• Characterizing Flavor(s) (e.g., none, tobacco, menthol)</td>
</tr>
<tr>
<td></td>
<td>• Source of energy (e.g., charcoal, electrical heater)</td>
</tr>
<tr>
<td></td>
<td>• Additional properties needed to uniquely identify the tobacco product (if applicable)</td>
</tr>
</tbody>
</table>

Clarification of Names for New and Predicate Tobacco Products

When identifying a new or predicate tobacco product using a different name than previously used in the SE Report or used in other submissions (e.g., a standalone grandfather submission), it is important to identify whether the characteristics are identical to the tobacco product with the previous name or have been modified. If the characteristics are identical, you should include a statement to this effect within the SE Report (e.g., “______” had a name change to “_______” and all characteristics are identical; the only difference is the product name). If the characteristics are not identical, each difference should be described. You may also list all the names (aliases) that are used to identify the same tobacco product (e.g., Tobacco Product A is also named Tobacco Product X and Z and all tobacco products are

\(^1\) The characterizing flavors noted are some of the examples included in section 907 of the FD&C Act. This includes flavors such as tobacco and menthol, which are sometimes added to certain components or parts (e.g., paper) of the tobacco product.

\(^2\) For example, non-combusted cigarette is one where the tobacco is only heated but not burned.
manufactured with the same characteristics). It is important to note that, if the characteristics of the
tobacco product have been modified during the application review process (e.g., within an SE Report
amendment), the modified product will not be reviewed, as it is considered a different tobacco product
and requires a separate application.

Evidence of an Eligible Predicate Tobacco Product

An eligible predicate tobacco product is either a grandfathered tobacco product (i.e., commercially
marketed in the United States other than exclusively in test markets as of February 15, 2007) or a
tobacco product previously found substantially equivalent by FDA.

If you select a predicate tobacco product that is grandfathered, you may reference the submission
tracking number (STN) and product name of the standalone grandfather submission if one exists.
Alternatively, you can provide specific information sufficient to support a grandfathered determination:

1. Identification of the predicate tobacco product, including but not limited to the name, category,
   subcategory, package type, package quantity, characterizing flavor, and other additional
   properties necessary to uniquely identify the product (e.g., length, diameter, and ventilation for
   combusted, filtered cigarettes)

2. Adequate information to demonstrate that the tobacco product was commercially marketed
   (other than exclusively in test markets) in the United States as of February 15, 2007. FDA
   interprets “as of” to mean “on.” If you cannot provide documentation that the tobacco product
   was specifically commercially marketed on February 15, 2007, FDA suggests that you provide
documentation of commercial marketing for a reasonable period of time before and after
February 15, 2007. Examples of such information may include, but are not limited to:
   
   • Dated copies of advertisements
   • Dated catalog pages
   • Dated promotional material
   • Dated trade publications
   • Dated bills of lading
   • Dated freight bills
   • Dated waybills
   • Dated invoices
   • Dated purchase orders
   • Dated customer receipts
   • Dated manufacturing documents
   • Dated distributor or retailer inventory lists
   • Any other document you believe demonstrates that the tobacco product was
     commercially marketed (other than exclusively in test markets) in the United States as
     of February 15, 2007

If applicable, you should include a brief statement identifying and explaining all citations and
abbreviations (e.g., item number and/or product description) used in the documentation that
reference the predicate tobacco product.
3. A statement that the predicate tobacco product was not exclusively in a test market as of February 15, 2007.

4. A brief description of how the predicate tobacco product is used by the consumer.

If you select a predicate tobacco product that was previously found substantially equivalent, provide the STN and predicate tobacco product name used within that submission (i.e., SE Report where the new tobacco product was found to be substantially equivalent).

**Use of a Predicate Tobacco Product You No Longer Manufacture**

If you no longer manufacture the predicate tobacco product, you should still fully characterize the predicate tobacco product in order for FDA to determine all differences in characteristics between the new and predicate tobacco products. Data on the predicate tobacco product may be required to demonstrate substantial equivalence of the new tobacco product. Some potential options for obtaining data on the predicate tobacco product include:

1. Manufacture the predicate tobacco product at present day, consistent with the product composition and design specifications in place at the time the predicate tobacco product was originally manufactured. In this case, design parameter data should be accompanied by documentation demonstrating that the manufacture of the predicate tobacco product at present day is reflective of the predicate tobacco product at the time of original manufacture. Where any difference exists between the present-day predicate tobacco product design parameters, components, or constituents and the original predicate tobacco product, those differences should be noted, and the present-day predicate tobacco product will be considered a surrogate tobacco product (see “Use of a Surrogate Tobacco Product” below).

2. Identify another, currently available tobacco product with design parameters, components, and constituents similar to the predicate tobacco product. This tobacco product will be considered a surrogate tobacco product (see “Use of a Surrogate Tobacco Product” below). Where any difference exists between the surrogate tobacco product design parameters, components, or constituents and the predicate tobacco product, those differences should be noted.

**Use of a Predicate Tobacco Product that You Do Not Own**

If you do not own the predicate tobacco product, you should still provide full characterization of the predicate tobacco product. Without this information, FDA cannot determine what all of the differences in characteristics of the new and predicate tobacco products are. For example, see “Adequate Tobacco and Ingredient Information” below. An explanation of the means by which you obtained the supplied information and certification that you have access to the product composition information for the predicate tobacco product from the manufacturer is necessary.

**Use of a Surrogate Tobacco Product**

A predicate tobacco product must have been commercially marketed in the United States (other than exclusively in test markets) as of February 15, 2007, or previously found to be substantially equivalent by
FDA. A new tobacco product must be compared to a predicate tobacco product for FDA to determine whether the new tobacco product is substantially equivalent; all SE orders issued by FDA are based on a comparison of the new tobacco product to a predicate tobacco product.

In some cases, however, an applicant may use a surrogate tobacco product (a tobacco product that is neither the new or predicate tobacco product) to provide test data (e.g., harmful and potentially harmful constituents [HPHC] test data). Data for the surrogate tobacco product are provided in place of data for the new or predicate tobacco product when data are not available for the new or predicate tobacco product. In order for FDA to evaluate the surrogate tobacco product for its suitability (i.e., whether the data for the surrogate tobacco product can be extrapolated to the new or predicate tobacco product), you should provide detailed information about a tobacco product’s characteristics, including design parameters, ingredients, tobacco blend, and component composition. An SE Report may include a surrogate new tobacco product, a surrogate predicate tobacco product, or both. If there is insufficient data to justify using a product as a surrogate, FDA cannot issue an SE order (assuming that this data is necessary to demonstrate that differences in characteristics between the new and predicate tobacco products do not cause the new tobacco product to raise different questions of public health).

As an example, an SE Report for a cigarette may include HPHC data for a surrogate predicate tobacco product because the applicant no longer manufactures the predicate tobacco product but manufactures the surrogate tobacco product and, therefore, can analyze it for HPHC quantities. In this example, the SE Report should include tobacco blend information for the predicate and surrogate predicate tobacco products demonstrating that the products have identical blends (e.g., identical tobacco and additives in the filler). The applicant could indicate that, because of the identical blends, tobacco-specific nitrosamine (TSNA) filler data for the surrogate predicate tobacco product can be extrapolated to the predicate tobacco product.

**Adequate Tobacco and Ingredient Information**

Your SE Report should provide information about tobacco and other ingredients in all components of the new and predicate tobacco products. The information provided for all ingredients should include sufficient detail to fully identify the composition of the new and predicate tobacco products. Your SE Report should provide a detailed list of ingredients in the new and predicate tobacco products, including the following:

- Ingredient names and absolute quantities (e.g., mg/cigarette) for all components
- Single ingredient names and absolute quantities in each complex ingredient (including reconstituted tobacco)
- Uniquely identifying information for all tobacco (e.g., tobacco type)
- Uniquely identifying information for all ingredients (e.g., CAS #, function)

If your SE Report contains ingredient quantities that are reported with values such as “less than”, “<”, “NA”, “N/A”, “blank”, or “shaded quantities” (e.g., shaded cells in Excel spreadsheets), additional explanation of the meaning of these values should be provided. Because what is being reported may be unclear, it would be helpful to provide justification for reporting these types of values in your SE Report.
Complex Ingredients

When providing a list of ingredients, you should provide full information regarding complex ingredients. For example, your SE Report should provide the names, functions, and quantities (e.g., mg/cigarette) of the single ingredients that comprise the complex ingredient (e.g., a flavoring mixture or casing). It is important to distinguish between complex ingredients made to your specifications and those that are not. For all complex ingredients made to your specifications, you should provide complete information according to FDA’s Guidance for Industry Listing of Ingredients in Tobacco Products. For complex ingredients that are not made to your specifications, you should provide complete information on the single ingredients that comprise these complex ingredients. If applicable, we suggest that you work with your ingredient supplier to submit a tobacco product master file (TPMF) so that FDA can determine whether differences in these complex ingredients cause the new tobacco product to raise different questions of public health. Additionally, for all complex ingredients, you should ensure that the single ingredient quantities add up to 100%.

Referencing a Tobacco Product Master File (TPMF)

A Tobacco Product Master File (TPMF) is submitted information that may be referenced by an authorized party in support of an application. When relying on information in a TPMF, your SE Report should reference the TPMF, cite the TPMF submission tracking number (STN), identify specific sections or types of information being referenced (e.g., ingredient data), and cite the owner of the TPMF. Additionally, your submission should include a letter of authorization (LOA) from the TPMF owner allowing FDA to review the information in the TPMF.

Use of Studies that Do Not Include the New and Predicate Products

If referencing research studies, you should explain how each reference supports the specific comparison between the new and predicate tobacco products. You should provide a rationale explaining how data generated using the experimental cigarettes evaluated in these references can be extrapolated to the new and predicate tobacco products subject of your SE Report, taking into account cigarette composition, smoke dilution methods, in vitro and in vivo exposure regimens, and data analysis methods. Explain how data extrapolated from these references supports the conclusion that the different characteristics in the new tobacco product compared to the predicate tobacco product do not cause the new tobacco product to raise different questions of public health.

Addressing Toxicity Caused by Ingredient Changes

When addressing the potential effects of ingredient changes, you should account for the potential toxicity of the changed ingredient via the route of exposure (i.e., inhalation), and the effect of the changed ingredient on HPHC delivery (e.g., combustion of the ingredient to form an HPHC). For a new and predicate tobacco product comparison, there may be multiple ways to address the toxicological differences that may result from ingredient changes. Different approaches that may address ingredient changes include:

1. HPHC information showing that there are no increases in HPHC delivery in the new tobacco product relative to the predicate tobacco product.
2. Battery of in vitro studies with a supporting rationale for how the submitted studies address the human cancer risk and non-cancer hazards expected because of the HPHC increases measured in the new tobacco product. Such studies could also potentially address concerns about the possible human health effects of ingredients in their unchanged form.

3. Toxicological analyses of ingredients or HPHCs that have been or can be used to establish health protective reference values (e.g., toxicological analyses conducted by the Environmental Protection Agency or toxicological information from the European Food Safety Authority) applicable to anticipated human exposures from use of the new tobacco product and how the reference values address the toxicological effects expected from the new tobacco product’s ingredients or HPHCs. Note that reference values based on non-cancer endpoints do not support carcinogenic HPHCs. In the absence of compelling data supporting a dose threshold below which the carcinogenicity of a compound definitively does not occur, it is a standard assumption and toxicological practice to assume a linear relationship between the dose of a carcinogen and an increased risk of cancer.

In these analyses, it is important to account for the following parameters:

- Route of administration in the study compared to route of exposure from use of the new and predicate tobacco products
- Relevance of animal species tested
- Dose-response profile
- Exposure frequency and duration
- Identifiers of adverse or critical effects, point of departure (e.g., no observable adverse effect level (NOAEL), lowest observable adverse effect level (LOAEL))
- Biological significance of response
- Relevance of uncertainty factors used
- Adjustment of the critical effect level to the dose metric of interest
- Species strain- and sex-specific effects
- Interpretation of results
- Availability of supporting evidence (e.g., read-across of toxicity data using structure-activity relationships, computational structure-activity relationship models with human expert interpretation to predict toxicity) and relevance of results to humans
- Available information on the metabolic fate and disposition of ingredients

Use of Interchangeable Materials

If you select new or predicate tobacco products that are composed of interchangeable materials, each unique combination of ingredients is considered a unique tobacco product. In accordance with Section 910(a)(1)(B) of the FD&C Act, each product modification, including use of an alternate material, constitutes a new tobacco product. A material is an alternate material if it has any difference in composition (e.g., ingredients, additives, biological organisms) or design parameters (e.g., target specifications, range limits). Each new and predicate tobacco product must consist of a single combination of components and structural materials. Therefore, your SE Report should identify the following if the new or predicate tobacco products contain interchangeable ingredients:
1. Every unique material combination in the predicate tobacco product that you are comparing to the new tobacco product in accordance with Section 910(a)(2)(B) of the FD&C Act.

2. Every unique material combination in the new tobacco product. [Insert the following sentence for Provisional SE Reports only]. Each specific combination of materials will be considered a single new tobacco product and evaluated individually in accordance with Section 910(a)(2)(B) of the FD&C Act.

3. A list of ingredients and ingredient quantities for each identified material in each new and predicate tobacco product.

4. Target specifications and upper and lower range limits for all design parameters for each material in each new and predicate tobacco product.

5. Test data (i.e., measured values of design parameters), including test protocols, quantitative acceptance criteria, data sets, and a summary of results. All of this information should be provided for any design parameter that differs between the new and predicate tobacco products.

Certificates of analysis (COAs) from the material supplier may provide some of the information listed above. If you choose to provide COAs for any of the parameters, the COAs should include target specification, quantitative acceptance criteria, parameter units, test data average value, and the minimum and maximum values of the test data. COAs should be complete and unaltered COAs from the material supplier.

Additionally, if a difference exists between the new and predicate tobacco products, you should provide justification for the difference and a rationale for why the difference does not cause the new tobacco product to raise different questions of public health. To clearly identify the specific new and predicate tobacco products in your SE Report, some options include:

1. Identify a single unique predicate tobacco product (with corresponding ingredients) composed of a single component material (e.g., filter tow, plug wrap). Additionally, select and identify a single new tobacco product (with corresponding ingredients) composed of a single material. In this case, the new tobacco product would be the only version of the new tobacco product considered for evaluation of substantial equivalence with the identified predicate tobacco product.

2. If you need to list interchangeable materials for the new or predicate tobacco product (or both), you may choose to demonstrate that the use of interchangeable materials does not cause the new tobacco product(s) to raise different questions of public health. To do this, identify every unique new and predicate tobacco product that may result from the integration of each combination of interchangeable materials. Each identified new and predicate tobacco product should consist of a single material combination. Target specifications, upper and lower range limits, and data generated from testing of applicable design parameters and HPHCs should be provided for each unique new and predicate tobacco product.

3. If you need to list interchangeable materials for the new or predicate tobacco product (or both), you may choose to provide a “bracketing” approach to demonstrate that the interchangeable materials do not cause the new tobacco product(s) to raise different questions of public health. To do this, you should specify two unique versions of the new tobacco product, and if
the predicate tobacco product contains interchangeable materials, two unique versions of the predicate tobacco product:

- For one of the unique versions of the new tobacco product, identify a single set of interchangeable materials that results in the highest HPHC yields generated through integration of the interchangeable materials.
- For the other unique version of the new tobacco product, identify a single set of interchangeable materials that results in the lowest HPHC yields generated through integration of the interchangeable materials.
- For one of the unique versions of the predicate tobacco product, identify a single set of interchangeable materials that results in the highest HPHC yields generated through integration of the interchangeable materials.
- For the other unique version of the predicate tobacco product, identify a single set of interchangeable materials that results in the lowest HPHC yields generated through integration of the interchangeable materials.

Provide a justification for why each version of the new and predicate tobacco products is representative of the highest and lowest HPHC yields from the products. Additionally, for each version specified, you should provide target specifications, upper and lower range limits, and data generated from testing of applicable design parameters and HPHCs for all of the identified new and predicate tobacco products.

**Nicotine Yield**

Your SE Report should provide the nicotine yields from the new and predicate tobacco products. Because nicotine is an addictive component of all tobacco products, comparative data for this ingredient is critical to allow FDA to make a determination of potential impact on public health. You should provide data on the total nicotine yield of the new tobacco product based on at least three measurements. If the nicotine yields are different between the new and predicate tobacco products, you should provide scientific evidence to demonstrate that the increase or decrease in nicotine content/yield does not cause the new tobacco product to raise different questions of public health relating to tobacco addiction.

**HPHC Yields**

It is recommended that all SE Reports contain HPHC yield data for the new and predicate tobacco products. Additionally, it is important to note that the provisions in Section 915 of the FD&C Act do not apply to your SE Report submitted under Section 905(j)(1)(A)(i) of the FD&C Act. When viewing differences in characteristics, you should provide scientific evidence and a rationale to address why these differences do not cause the new tobacco product to raise different questions of public health. You should consider measuring HPHCs that would be impacted by the differences in tobacco blends, ingredients, and product design between the new and predicate products under ISO and Canadian Intense smoking regimens. Appropriate measures should be taken to minimize data variability and systematic bias. Suggested measures include, but are not limited to, using the same laboratory, the same type of smoking machine (when applicable), the same methods, similar sample storage conditions and duration, and testing within a similar timeframe.
You should provide the following information about HPHC testing so that FDA can fully evaluate the differences in HPHC yields between the new and predicate tobacco products:

1. Reference product datasets (e.g., 1R6F)
2. Complete description of quantitative test protocols and method used
3. Testing laboratory and its accreditation(s)
4. Method validation status and validation reports and data for each analytical method
5. Length of time between date(s) of manufacture and date(s) of testing
6. Number of replicates
7. Standard deviation(s)
8. Complete data sets
9. A summary of the results for all testing performed
10. Storage conditions prior to initiating testing

If your test methods are national or international test standards, identify any deviations from those standards.

If your predicate tobacco product is not available for testing, there are options you may choose to pursue to try to demonstrate substantial equivalence. See above for information on surrogate tobacco products.

**Use of QRA to Address HPHC Increases**

A quantitative risk assessment (QRA) approach may be useful in limited situations where there are offsetting HPHC increases and decreases. Further, there are some cases in which the HPHC offsetting is so obvious that a qualitative approach may be sufficient – such as when there are sharp decreases in several high-potency carcinogens and a small increase in a carcinogen of lower potency. If there are multiple HPHC increases without concomitant HPHC decreases, a well-conducted QRA is unlikely to address the increases in toxicological hazard and risk associated with the HPHC increases. In cases where there are clear HPHC increases in the new tobacco product compared to the predicate tobacco product without offsetting HPHC decreases, a well-conducted QRA would simply reflect the difference in hazard and risk between the new and predicate tobacco products and would therefore not add support to the contention that the new tobacco product does not raise different questions of public health.

If a QRA is submitted in your SE Report, you should address whether any elevated levels of HPHCs (and other constituents of concern) in the new tobacco product, as compared to the predicate tobacco product, increase the overall cancer risk and non-cancer hazard of the new tobacco product as compared to the predicate tobacco product. The design of the QRA should outline the specific question(s) addressed by the QRA and clearly define the overall risk model. Sufficient detail is needed to adequately compare the cumulative hazard and risk for the specific new and predicate tobacco product pair. The QRA should clearly outline how specific differences between the new and predicate tobacco products change the total hazard and risk of each product. For FDA to evaluate a QRA, it should, at a minimum, include the following information:

1. A well-developed and scientifically supported risk assessment, including a problem formulation, hazard identification, dose-response assessment, exposure assessment and risk
characterization, as outlined by the National Research Council.\(^3\) Also include identification and characterization of uncertainty and variability throughout the elements of the risk assessment process

2. All raw data, equations, assumptions, parameters, outputs, and references used, and justification that the QRA is appropriate for comparing the relative human health risks and hazards from use of the new and predicate tobacco products for the relevant user population

3. All relevant measured HPHCs or other constituents of potential toxicological concern, employing, as much as possible, a consistent risk assessment approach for all constituents being evaluated

4. Evidence that the constituents considered in the composite QRA are representative of potential differences in the cumulative hazard and risk of the new and predicate tobacco products, and evidence that the evaluation can discern a difference in hazard and risk between the new and predicate tobacco products

In vivo nonclinical studies are not required to address ingredient changes. FDA supports reducing the reliance on animal testing where adequate and scientifically valid animal alternatives can be substituted. When using any toxicology study data collected, as well as referencing any publicly available toxicology information on published research studies, you should explain how the study data or information in each reference supports a toxicological evaluation of the comparison between the new and predicate tobacco products. Aspects to consider include a rationale explaining how data generated using a specific tobacco product (e.g., experimental cigarette, reference tobacco product, or a marketed tobacco product other than the new and predicate tobacco products) evaluated in any studies or references can be extrapolated to the new and predicate tobacco products and specific product differences. This rationale should take into account cigarette composition, smoke dilution methods, in vitro and in vivo exposure regimens, and data analysis. Also, you should state the limitations of the methods used in the study. In addition, you should explain in a narrative how data extrapolated from any referenced studies support the conclusion that the different characteristics do not cause the new tobacco product to raise different questions of public health.

**Use of a Model**

If you choose to use a model, you should provide all design characteristics and all ingredients for all tobacco products modeled. A modeling approach is not likely to be useful in circumstances where there are many ingredient differences between the new and predicate tobacco products. Ingredient changes alter the physicochemical characteristics of a new tobacco product, especially if that tobacco product combusts, heats, or otherwise applies energy to a mixture. Therefore, ingredient changes can influence the toxicological potential of a new tobacco product relative to a predicate tobacco product. An empirical test sufficiently powered to elucidate potential differences between a new and predicate tobacco product would likely show physicochemical or toxicological differences between the new and predicate tobacco products. Similarly, a well-conducted physicochemical or toxicological model will likely show differences in health risk to the user if there are a large number of ingredient changes to the

---

new tobacco product relative to a predicate tobacco product. FDA recommends that applicants discuss the use of any models addressing toxicity or health risks used to support an SE Report with FDA prior to the start of scientific review of the SE Report.

[INCLUDE: AMENDMENTS AND ENVIRONMENTAL ASSESSMENTS FOR ACKNOWLEDGEMENT AND NOTIFICATION LETTERS ONLY. FOR ALL OTHER LETTERS CONTINUE TO THE OPTIONS SECTION BELOW]

**Amendments**

All information in SE Reports should be consistent between the original submission and any amendments. If you provide updated information in an amendment, FDA will consider that information to supersede the information provided in the original submission, except for measured values (e.g., test data, HPHC data). For measured values, applicants should provide rationale for why the updated data are appropriate for consideration. If rationale is not provided, measured values will be combined with previous measured values for evaluation.

[FOR PROVISIONAL SE REPORTS, INCLUDE:]

**Environmental Assessment**

In general, granting an order finding a tobacco product substantially equivalent under Section 910(a)(2)(B) of the FD&C Act is a class of action that has a categorical exclusion in place and does not normally require the preparation of an environmental assessment (EA) or an environmental impact statement (EIS). However, as required under 21 CFR 25.21 and 40 CFR 1508.4, FDA will require preparation of at least an EA for any specific action that normally would be excluded if extraordinary circumstances are present such that the specific proposed action may have the potential to significantly affect the quality of the human environment. If you elect to request a categorical exclusion, it should be submitted in accordance with 21 CFR 25.15 and include:

1. A statement of compliance with the categorical exclusion criteria
2. A statement that, to the submitter’s knowledge, no extraordinary circumstances exist

A statement that no extraordinary circumstances exist could read as follows: “The proposed action of finding [name of product] substantially equivalent under Section 910(a)(2)(B) of the FD&C Act is a class of actions under 21 CFR 25.35(a). The proposed action complies with the criteria for this claim of categorical exclusion. To the best of our knowledge, no extraordinary circumstances exist that require the submission of an environmental assessment or an environmental impact statement.”

[END]

[FOR REGULAR SE REPORTS, INCLUDE:]

**Environmental Assessment**

Granting an order finding a tobacco product substantially equivalent under Section 910(a)(2)(A)(i) of the FD&C Act is not a class of action that has a categorical exclusion in place and thus requires an environmental assessment (EA). The following information is needed to determine whether to prepare an environmental impact statement (EIS) or finding of no significant impact (FONSI). An inadequate resolution of this issue may delay issuance of an order of substantial equivalence. Please consider the following information:
• When providing a bundled submission containing multiple products, a unique EA should be written for each new tobacco product.
• EAs will be available to the public in accordance with 40 CFR 1506.6.
• To assist in preparing an EA, you can review EAs that have been posted on the CTP website.
• Each EA should address the environmental effects of the new tobacco product manufacturing, use, or disposal and include the following:
  o The affected environment – Provide a description of the land use around the manufacturing facility, including an aerial photograph showing the described area and the environment where the product will be used or disposed.
  o Air quality – Provide details regarding any changes in compounds emitted during manufacturing, use, and disposal (new compounds emitted and/or increases in current emissions). Discuss any environmental effects due to these changes.
  o Water resources – Discuss the potential that the new tobacco product will impact wastewater discharges and the effects on water resources.
  o Land use and zoning – Discuss the potential that the product will require an expansion of the manufacturing facility and if so, the effects on land use and zoning due to that expansion.
  o Biological resources – Discuss the potential to jeopardize the continued existence of any listed species under the Endangered Species Act.
  o Geological features and soils – Discuss the potential for the new tobacco product to lead to soil changes; discuss the potential effects on land conversion of prime farmland, unique farmland, or farmland of statewide importance to non-agricultural use.
  o Socioeconomics and environmental justice – Discuss the potential to impact socioeconomics and the impacts on employment revenue or taxes.
  o Solid waste and hazardous waste – Discuss the potential to change current solid waste and hazardous waste generation, the need for new or revised waste permits, and the need for new landfill construction.
  o Floodplains, wetlands and coastal zones – Discuss the potential of any land disturbance.
  o Regulatory compliance – Provide detailed information for permits for (1) air emissions, (2) storm water, and (3) wastewater. Include information on the type of permits, the permit numbers, and the expiration dates of the permits.
  o Cumulative impacts – Discuss the potential that the new tobacco product will incrementally increase or change the chemicals released to the environment. Also, describe potential past, current, and foreseeable future environmental effects associated with air quality, water resources, land use and zoning, biological resources, geological features and soils, socioeconomics and environmental justice, solid waste and hazardous waste, floodplains, wetlands and coastal zones.
• Each EA should include information about the predicate tobacco product and address the following:
  o Whether the predicate tobacco product will continue to be commercially marketed in the United States. If both the new and predicate tobacco products will be manufactured for commercial distribution at the same time, the EA should describe how that will change resource use and environmental impacts.
  o Current market volume, in metric tons, for the predicate tobacco product, and market volume projections for both the new and predicate tobacco products for the first and fifth years following the issuance of a marketing order for the new tobacco product.
[OPTIONS – SELECT APPROPORATE OPTIONS BASED ON PRODUCT SUBCATEGORY TO INCLUDE IN LETTER:]

[Option 1: Use if product subcategory is Combusted, Filtered]

Design Parameter Information

Design parameters are foundational information that allows FDA to better understand the tobacco product, offers insight into potential effects on the cigarette smoke constituents, and are necessary to fully characterize the new and predicate tobacco products. The design parameters necessary to control the manufacture of your tobacco product may not be sufficient to provide the complete characterization necessary for the comparison of two products. However, those critical design parameters will provide most of the information that FDA needs. Often manufacturers maintain this type of information in technical data sheets for each product. Where these data sheets are available, you should provide them and all accompanying documentation (e.g., Certificates of Analysis (COAs), other specification documents). Where these data sheets are not available for the new and predicate tobacco products, you should provide the materials that are available. You should provide target specifications and upper and lower range limits for all of the following design parameters for each new and predicate tobacco product, submitted either within the data sheets or SE Report:

1. Cigarette length (mm)
2. Cigarette diameter (mm)
3. Ventilation (%)
4. Tobacco filler mass (mg)
5. Tobacco rod density (g/cm³)
6. Tobacco moisture (%)
7. Tobacco cut size (mm) or (CPI)
8. Cigarette paper base paper porosity (CU)
9. Cigarette paper band porosity (CU)
10. Cigarette paper band width (mm)
11. Cigarette paper band space (mm)
12. Tipping paper length (mm)
13. Filter efficiency (%) {If no filter efficiency data is available for the products, include information sufficient to show that the cigarette filter is unchanged [e.g., denier per filament (DPF), total denier (g/9000m), and filter density(g/cm³)]}
14. Filter pressure drop (mm H₂O)
15. Filter length (mm)

For each of the above parameters, you should provide the necessary data on a per unit of measurement of product basis (e.g., tipping paper length should be reported in mm per cigarette). If a design parameter is not applicable (e.g., band porosity, if the cigarette paper does not contain bands), state as such and provide a rationale.

If your predicate tobacco product is a product that you do not manufacture, you should provide an explanation of the means by which you obtained the supplied information and certify that you have access to the product design information from the manufacturer. Alternatively, if you manufacture the predicate tobacco product, state as such.
If a difference exists in the target specifications or range limits between the new and predicate tobacco products, provide scientific evidence and a rationale for why the difference(s) does not cause the new tobacco product to raise different questions of public health.

In addition to the target specifications and upper and lower range limits, FDA will occasionally need data confirming that specifications are met. Specifically, test data is critical in cases where differences in the target specification exist or when the range limits of the new tobacco product are wider than those of the predicate tobacco product. For each of these design parameters you should provide the test data (i.e., measured values of design parameters), including test protocols, quantitative acceptance criteria, data sets, and a summary of the results for the new and predicate tobacco product. Provide the necessary data on a per unit of measurement of product basis (e.g., filter pressure drop should be reported in mm H₂O per cigarette). If a design parameter is not applicable (e.g., band porosity, if the cigarette paper does not contain bands), state as such and provide a rationale. For the design parameters that were tested according to national or international standards, identify the standards and state what deviations from the standards occurred (if any).

Test protocols are necessary so that FDA can determine whether the test data between the new and predicate products were collected under comparable conditions. If different test protocols were used for the new and predicate tobacco products, explain how the methods and the test data may be evaluated. If you do not or did not manufacture the predicate tobacco product, you are still expected to provide test data as indicated above.

[END OPTION 1]

[Option 2: Use if product subcategory is Combusted, Non-Filtered]

**Design Parameter Information**

Design parameters are foundational information that allows FDA to better understand the tobacco product, offers insight into potential effects on the cigarette smoke constituents, and is necessary to fully characterize the new and predicate tobacco products. The design parameters necessary to control the manufacture of your tobacco product may not be sufficient to provide the characterization necessary for the comparison of two products. However, those critical design parameters will provide most of the information that FDA needs. Often manufacturers maintain this type of information in technical data sheets for each product. Where these data sheets are available, you should provide them and all accompanying documentation (e.g., Certificates of Analysis (COAs), other specification documents) with your submission. Where these data sheets are not available for both the new and predicate tobacco products, provide the materials available. You should provide target specifications and upper and lower range limits for all of the following design parameters for each new and predicate tobacco product, submitted either within the data sheets or SE Report:

1. Cigarette length (mm)
2. Cigarette diameter (mm)
3. Ventilation (%)
4. Tobacco filler mass (mg)
5. Tobacco rod density (g/cm³)
6. Tobacco moisture (%)
7. Tobacco cut size (mm) or (CPI)
8. Cigarette paper base paper porosity (CU)
9. Cigarette paper band porosity (CU)
10. Cigarette paper band width (mm)
11. Cigarette paper band space (mm)

For each of the above parameters, you should provide the necessary data on a per unit of measurement of product basis. If a design parameter is not applicable (e.g., band porosity, if the cigarette paper does not contain bands), state as such and provide a rationale.

If your predicate tobacco product is a product that you do not manufacture, you should provide an explanation of the means by which you obtained the supplied information and certify that you have access to the product design information from the manufacturer. Alternatively, if you manufacture the predicate tobacco product, state as such.

If a difference exists in the target specifications or range limits between the new and predicate tobacco products, provide scientific evidence and a rationale for why the difference(s) does not cause the new tobacco product to raise different questions of public health.

In addition to the target specifications and upper and lower range limits, FDA will occasionally need data confirming that specifications are met. Specifically, test data is critical in cases where differences in the target specification exist or when the range limits of the new tobacco product are wider than those of the predicate tobacco product. For each of these design parameters you should provide the test data (i.e., measured values of design parameters), including test protocols, quantitative acceptance criteria, data sets, and a summary of the results for the new and predicate tobacco product. Provide the necessary data on a per unit of measurement of product basis (e.g., filter pressure drop should be reported in mm H₂O per cigarette). If a design parameter is not applicable (e.g., band porosity, if the cigarette paper does not contain bands), state as such and provide a rationale. For the design parameters that were tested according to national or international standards, identify the standards and state what deviations from the standards occurred (if any).

Test protocols are necessary so that FDA can determine whether the test data between the new and predicate products were collected under comparable conditions. If different test protocols were used for the new and predicate tobacco products, explain how the methods and the test data may be evaluated. If you do not or did not manufacture the predicate tobacco product, you are still expected to provide test data as indicated above.

[END OPTION 2]

[END OPTIONS]